News

AbbVie company Pharmacyclics and Janssen Biotech are jointly developing and commercializing Imbruvica, which is oral, once-daily therapy that inhibits Bruton’s tyrosine kinase (BTK) protein. The breakthrough therapy designation

Roche’s marketing authorization application of the drug has been validated by the EMA to treat relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), confirming that the

Sanofi will transfer ownership of the €11.4bn Merial animal health business to Boehringer in return for the latter’s consumer healthcare (CHC) business, valued at €6.7bn and €4.7bn of

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for

The transaction terms provided each outstanding share of Anacor to be converted into the right to get $99.25 net in cash without any interest but subject to required

It also entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of

Napabucasin is an orally administered cancer stemness inhibitor designed to inhibit cancer stemness pathways by targeting STAT3, and is currently being investigated in a global Phase III clinical

GVHD is a condition where the donated bone marrow or peripheral blood stem cells see the recipient’s body as foreign and attack the body. It is a significant

The US authorities have recommended against its use saying that the vaccine showed ‘poor or relatively lower effectiveness’ of LAIV from 2013 through 2016. CDS said in a